{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T16:33:24Z","timestamp":1721925204601},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,1]]},"DOI":"10.2169\/internalmedicine.1023-22","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T22:11:02Z","timestamp":1678831862000},"page":"3175-3181","source":"Crossref","is-referenced-by-count":3,"title":["Remission Induction of IgG4-related Membranous Nephropathy with Multitarget Therapy"],"prefix":"10.2169","volume":"62","author":[{"given":"Yoshitaka","family":"Furuto","sequence":"first","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Nephrology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Alexander MP, Larsen CP, Gibson IW, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 83: 455-462, 2013.","DOI":"10.1038\/ki.2012.382"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 78: 1016-1023, 2010.","DOI":"10.1038\/ki.2010.271"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masugata H, Senda S, Hoshikawa J, et al. Differences between hypertensive and atherosclerotic lesions in retinal arteries assessed by Scheie&apos;s classification in hypertensive patients following stroke. Clin Exp Hypertens 32: 335-340, 2010.","DOI":"10.3109\/10641960903443574"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Saeki T, Kawano M, Nagasawa T, et al. Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol 25: 99-109, 2021.","DOI":"10.1007\/s10157-020-01993-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fervenza FC, Downer G, Beck LH Jr, Sethi S. IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am J Kidney Dis 58: 320-324, 2011.","DOI":"10.1053\/j.ajkd.2011.05.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sueta S, Kondo M, Matsubara T, et al. Membranous nephropathy associated with type 1 autoimmune pancreatitis and dominant glomerular IgG4 deposit. CEN Case Rep 3: 18-23, 2014.","DOI":"10.1007\/s13730-013-0077-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cravedi P, Abbate M, Gagliardini E, et al. Membranous nephropathy associated with IgG4-related disease. Am J Kidney Dis 58: 272-275, 2011.","DOI":"10.1053\/j.ajkd.2011.05.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Stone JH. IgG4: a tantalizing link between causes of membranous glomerulonephritis and systemic disease. Kidney Int 83: 348-350, 2013.","DOI":"10.1038\/ki.2012.454"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jindal N, Yadav D, Passero C, et al. Membranous nephropathy: a rare renal manifestation of IgG4-related systemic disease. Clin Nephrol 77: 321-328, 2012.","DOI":"10.5414\/CN107037"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kanda H, Koya J, Uozaki H, et al. Membranous nephropathy with repeated flares in IgG4-related disease. Clin Kidney J 6: 204-207, 2013.","DOI":"10.1093\/ckj\/sfs180"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 366: 539-551, 2012.","DOI":"10.1056\/NEJMra1104650"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 361: 2135-2142, 2009.","DOI":"10.1056\/NEJMoa0903068"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nesheiwat Z, Daboul J, Merugu GP, Adapa S, Balla M. Membranous nephropathy and autoimmune hepatitis in the setting of acute <i>Helicobacter pylori<\/i> infection: a case report. J Med Case Rep 15: 308, 2021.","DOI":"10.1186\/s13256-021-02874-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Caliskan B, Yazici H, Caliskan Y, et al. The effects of <i>Helicobacter pylori<\/i> eradication on proteinuria in patients with primary glomerulonephritis. Int J Nephrol 2014: 180690, 2014.","DOI":"10.1155\/2014\/180690"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nagashima R, Maeda K, Yuda F, Kudo K, Saitoh M, Takahashi T. <i>Helicobacter pylori<\/i> antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch 431: 235-239, 1997.","DOI":"10.1007\/s004280050094"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sugimoto T, Furukawa T, Maeda T, et al. Marked reduction of proteinuria after eradication of gastric <i>Helicobacter pylori<\/i> infection in a patient with membranous nephropathy: coincidental or associated? Intern Med 46: 1483-1484, 2007.","DOI":"10.2169\/internalmedicine.46.0200"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huart J, Grosch S, Bovy C, Moutschen M, Krzesinski JM. IgG4-related membranous glomerulonephritis and generalized lymphadenopathy without pancreatitis: a case report. BMC Nephrol 18: 139, 2017.","DOI":"10.1186\/s12882-017-0561-2"},{"key":"18","unstructured":"18. Stone JH. IgG4-related disease: pathophysiologic insights drive emerging treatment approaches. Clin Exp Rheumatol 34: 66-68, 2016."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kr\u00e4mer BK, Montagnino G, Kr\u00fcger B, et al. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results. Transpl Int 29: 307-314, 2016.","DOI":"10.1111\/tri.12716"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kr\u00e4mer BK, Del Castillo D, Margreiter R, et al. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant 23: 2386-2392, 2008.","DOI":"10.1093\/ndt\/gfn004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yasuda H, Fukusumi Y, Ivanov V, Zhang Y, Kawachi H. Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton. FASEB J 35: e21983, 2021.","DOI":"10.1096\/fj.202101052R"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49: 141-175, 2010.","DOI":"10.2165\/11317350-000000000-00000"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19: 2001-2010, 2008.","DOI":"10.1681\/ASN.2007121272"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (aurora 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397: 2070-2080, 2021.","DOI":"10.1016\/S0140-6736(21)00578-X"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. El-Reshaid K, Al-Bader S, Madda J. Membranous glomerulopathy and massive cervical lymphadenopathy due to immunoglobulin G4-disease. Saudi J Kidney Dis Transpl 28: 149-153, 2017.","DOI":"10.4103\/1319-2442.198167"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1023-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T03:22:26Z","timestamp":1699068146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1023-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":25,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1023-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"article-number":"1023-22"}}